ストックスクリーナーアプリを入手
21.44
1.71%
0.3677
前日終値:
$21.07
開ける：
$21.31
24時間の取引高:
543.54K
Relative Volume:
0.87
時価総額：
$1.04B
収益：
$458.69M
当期純損益:
$11.68M
株価収益率:
89.25
EPS:
0.2402
ネットキャッシュフロー:
$14.58M
1週間 パフォーマンス:
+2.63%
1か月 パフォーマンス:
-5.88%
6か月 パフォーマンス:
-53.32%
1年 パフォーマンス:
-25.41%
1日の値動き範囲:
$21.09
$21.98
1週間の範囲:
$19.88
$21.98
52週間の値動き範囲:
$19.16
$48.25
Artivion Inc Stock (AORT) Company Profile
Compare AORT vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AORT
Artivion Inc
|
21.43 | 1.02B | 458.69M | 11.68M | 14.58M | 0.2402 |
ABT
Abbott Laboratories
|
89.84 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
309.68 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.97 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
47.02 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.14 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Artivion Inc Stock (AORT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2025-08-13 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2025-06-17 | 開始されました | Canaccord Genuity | Buy |
| 2024-10-23 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-09-27 | 繰り返されました | Lake Street | Buy |
| 2022-08-08 | 開始されました | Lake Street | Buy |
| 2022-03-03 | 開始されました | Stifel | Buy |
すべてを表示
Artivion Inc (AORT) 最新ニュース
Artivion’s Andrew Green sells $910,738 in company stock - Investing.com UK
Artivion’s Andrew Green sells $910,738 in company stock By Investing.com - Investing.com India
Artivion (AORT) SVP exercises options and sells 44,001 shares under 10b5-1 plan - Stock Titan
Precision Trading with Artivion Inc Com (AORT) Risk Zones - Stock Traders Daily
AORT Q1 2026 Earnings: EPS Misses Estimates as Profitability Pressures EmergeAnalyst Coverage Count - The League of Women Voters of Texas
What Artivion (AORT)'s Strong Q1 Growth But Lowered Guidance Means For Shareholders - Yahoo Finance
Artivion secures FDA approval for NEXUS aortic arch system - MSN
[144] ARTIVION, INC. SEC Filing - Stock Titan
Will Stronger Revenue but Softer Outlook Change Artivion's (AORT) Growth-Quality Narrative? - simplywall.st
Artivion to present at 2026 Truist Securities MedTech Conference with live webcast on June 16 - Pluang
Artivion to Participate in the 2026 Truist Securities MedTech Conference - marketscreener.com
Cardiac surgery company Artivion joins 2026 Truist MedTech conference in Boston - Stock Titan
Artivion (AORT) Stock Forum and Discussion - Moomoo
Artivion (AORT) Q1 2026 Earnings: Revenue Growth of 17.5% Meets Expectations Amid Mixed Industry Results - IndexBox
Q1 Earnings Outperformers: Artivion (NYSE:AORT) And The Rest Of The Medical Devices & SuppliesCardiology, Neurology, Vascular Stocks - Yahoo Finance
Lake Street Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Artivion (AORT) SVP discloses common stock, RSU and option holdings - Stock Titan
Estate move: Artivion (AORT) director moves 6,325 shares into trust - Stock Titan
Artivion, Inc. has exercised option to acquire Endospan Ltd. for approximately $380 million. - marketscreener.com
Artivion Inc. (AORT) Slips 0.76% as Stock Tests Key Support Near $19.85Hull Moving Average - thelegaladvocate.com
Artivion secures FDA approval for NEXUS aortic arch device, weighs Endospan acquisition - MSN
A Quick Look at Today's Ratings for Artivion(AORT.US), With a Forecast Between $36 to $48 - Moomoo
Stifel Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Stifel reiterates Artivion stock rating on surgeon survey results - Investing.com
Stifel reiterates Artivion stock rating on surgeon survey results By Investing.com - Investing.com South Africa
AORT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Artivion (AORT) Earnings Date and Reports 2026 $AORT - MarketBeat
Artivion Inc. (AORT) Holds Near Support as Mild Pullback Tests Recent RangeIchimoku TK Cross - thelegaladvocate.com
Artivion Inc. (AORT) Faces Selling Pressure as Shares Dip Below Key Moving AveragesTechnical Analysis - thelegaladvocate.com
Artivion Q1 earnings call highlights - MSN
AORT News | ARTIVION INC (NYSE:AORT) - ChartMill
Artivion (AORT) Q1 earnings and revenues surpass estimates - MSN
Artivion (AORT) director corrects details of restricted stock award - Stock Titan
Director at Artivion (NYSE: AORT) awarded 7,576 restricted shares - Stock Titan
Artivion Completes Endospan Acquisition, Expands Aortic Arch Portfolio With FDA-Approved NEXUS System - MedTech Intelligence
Artivion (NYSE:AORT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of - Yahoo Finance
Artivion | 4: Statement of changes in beneficial ownership of securities-Director ACKERMAN THOMAS F - Moomoo
Artivion (AORT) director receives 7,850-share stock award, now holds 56,938 - Stock Titan
Artivion Earnings Call Balances Growth With Caution - TipRanks
Artivion closes Endospan buyout to acquire recently approved heart device - MedTech Dive
Artivion Completes Acquisition of Endospan, Secures FDA Approval for NEXUS Aortic Arch System - Minichart
Artivion Bets On Full Aortic Arch Suite After Endospan Deal - Yahoo Finance
Artivion strengthens aortic arch portfolio with $135m Endospan acquisition - MSN
Artivion (AORT) Completes Acquisition of Endospan for Aortic Sol - GuruFocus
Artivion Closes $175 Million Acquisition of Endospan - Moomoo
Artivion Closes $175M Deal for Aortic Arch Maker Endospan - Medical Product Outsourcing
Artivion completes $175M acquisition of Endospan - Investing.com UK
Artivion Inc (AORT) 財務データ
収益
当期純利益
現金流量
EPS
1.34%
0.97%
大文字化:
|
ボリューム (24 時間):